(Q45765615)

15 December 2017

title

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. (English)

1 reference

15 December 2017

0 references

1 reference

3

1 reference

15 December 2017

Pierre Van Damme

series ordinal

4

object named as

Pierre Van Damme

1 reference

15 December 2017

David FitzSimons

1

1 reference

15 December 2017

Greet Hendrickx

series ordinal

2

1 reference

15 December 2017

language of work or name

English

0 references

publication date

8 November 2012

1 reference

15 December 2017

published in

Vaccine

1 reference

15 December 2017

volume

31

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

584-590

1 reference

15 December 2017

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B and the need for a booster dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Determination of immune memory to hepatitis B vaccination through early booster response in college students.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term protection against carriage of hepatitis B virus after infant vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

Potential threat of drug-resistant and vaccine-escape HBV mutants to public health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.101

10.1016/J.VACCINE.2012.10.101

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017